Katy Rezvani, M.D., Ph.D
@lab_rezvani
Vice President & Head, Institute of Cell Therapy Discovery & Innovation, MD Anderson Cancer Center
Many congrats Alex on this very well-deserved #societyfornaturalimmunity travel award! Your 4 years of work developing GW CRISPR screens in primary CAR-NK cells is paying off! Excited to see how your data will shape the future of NK cell therapy. @MDAndersonNews #NK2025
Back from an amazing #NK2025! 🧬✨ Honored to present our work on genome-wide CRISPR screens to boost CAR-NK cell potency💥Immensely grateful to my incredible mentor, @lab_rezvani 🙏🌟 for her support and to the #SocietyforNaturalImmunity for the travel award🙌 #NKcells #ACT
Thank you, Dr. Pisters for your inspiring vision. Our team of dedicated scientists and clinicians is committed to advancing cell therapies that will bring transformative treatments to patients with cancer, autoimmune disorders and infection diseases @MDAndersonNews #CellTherapy…
Today, @MDAndersonNews launched the Institute for Cell Therapy Discovery & Innovation, which aims to lead the world in developing and advancing cell therapies for patients in need. By uniting top scientists and clinicians, we look forward to uncovering new insights in immunology…
Thank you Dr Pisters for attending today’s EAB meeting and for your inspiring vision and steadfast support. Deepest thanks also to our extraordinary EAB members: Drs Carl June, Lewis Lanier, Nicholas Huntington @Dr_Nick_Bikes , John DiPersio, Helen Heslop, Keith Sullivan,…
Pleased to join the first Institute for Cell Therapy Discovery & Innovation's External Advisory Board meeting. With their support and expertise, @MDAndersonNews is well-positioned to translate scientific breakthroughs into powerful cell-based treatments more efficiently, at lower…
Congrats to @Dr_Nick_Bikes and team on their Cancer Cell paper! CRISPR screens identify UBE2F and ARIH2 as key brakes on IL-15R signaling in NK cells. Targeting them improves NK & CAR-NK anti-tumor activity, uncovering promising targets for immunotherapy. #NKcells #CAR_NK #IL15
Excited to share our Cancer Cell @CellPressNews article on the discovery of the IL-15 Receptor "Regulome". A technical tour-de-force from the Immunology, computational biology & functional genomics teams @oNKo_innate @MonashBDI
Hind, many congratulations on this important work & sincere thanks to the brilliant co-authors who made it possible. I’m so proud of all you’ve achieved and wish you every success as you begin your independent career. Excited to see what comes next! rdcu.be/epuy6
🧵14/ This work wouldn’t have been possible without the incredible mentorship of @lab_rezvani, the brilliance of our lab members, our co-authors, and the generous support of our collaborators Dr. Toszka Bohn, Dr. Tobias Bopp, Sebastian Kunz, Dr. Huihui Fan, @abhinavjain_phd,…
Treating the untreatable - "Enhanced CAR T-Cell Therapy for Lymphoma after Previous Failure" @PennMedicine @nejm #immunotherapy nejm.org/doi/full/10.10…
Congratulations to @ABiederstadt_MD on an outstanding presentation #AACR25, showcasing a novel platform for genome-wide CRISPR screening in primary human CAR NK cells. So proud of your achievements and excited to watch your continued impact in the field. #NKcells @MDAndersonNews
Congratulations! Looking forward to your presentation. I have no doubt it’ll be amazing!
Very excited to share our work on targeting a checkpoint induced by CAR and cytokine signaling and exchange ideas at the Adoptive Cell Therapies session co-chaired by @sidichen @DJPowellLab at #AACR25. I hope to see you there 😊! @lab_rezvani @MDAndersonNews AACR: MD Anderson…
The AACR congratulates Crystal L. Mackall, MD, FAACR, who will be honored with the 2025 AACR-@CancerResearch Lloyd J. Old Award in Cancer Immunology at #AACR25. brnw.ch/21wRUDO #AACRFellows @StanfordMed @parkerici
Brilliant work! congratulations, @may_daher and @CollaSimona and co-authors. Fascinating insight into how early NK cell dysfunction contributes to immune escape in MDS, and a compelling case for the therapeutic potential of adoptive NK cell transfer. Looking forward to seeing…
Very excited to share our latest research article published with @SpringerNature in @NatureComms. We show that in early #MDS, NK cells share mutations with the malignant clones, becoming dysfunctional and failing to eliminate aberrant stem cells. This leads to immune evasion and…
Dear Leukemia friends, making U aware of this exceptional MDS symposium organized by Dr. @CollaSimona at @MDAndersonNews in May 2025! The speaker line up is phenomenal & the science is cutting edge. Register 👇🏼 join us & RT pls mdanderson.cloud-cme.com/course/courseo… #MDSsm
Please check out our paper published in @NatureMedicine on our Phase I trial of AFM13-precomplexed cord blood NK cells in relapsed/refractory CD30+ lymphomas. Led by Dr. Yago Nieto and an outstanding team of coauthors and collaborators, this study marks the first clinical…
Findings from a Phase I trial suggest natural killer cells pre-complexed with AFM13 has promise for specific patients with lymphoma and may be adapted for more cancer types in the future. Learn more: brnw.ch/21wRN45 #EndCancer
Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells @ImmunityCP cell.com/immunity/fullt…
Thank you Dr. Pisters - it was an honor to share the progress being made at the Institute for Cell Therapy Discovery & Innovation! Very grateful to @GHPartnership for the opportunity to showcase our efforts to bring transformative cell therapies to patients. Looking forward to…
It was a superb @GHPartnership Board Meeting today as @MDAndersonNews' Dr. Katy Rezvani shared the groundbreaking work underway within the Institute for Cell Therapy Discovery & Innovation. This area of science continues to develop in tremendous ways for the benefit of patients…
Congratulations to Dr. Rafet Basar for his outstanding presentation at ASTCT on the promise of cord blood therapies. His talk highlighted our work on engineered NK cells. Grateful for his amazing contributions to the field! #NKCells #ASTCT @MDAndersonNews @rftbsr9
Excited to share that my mentee, Ethan Ye Li, has received the ASCT New Investigator Award! So proud of his achievements - this is just the beginning. I have no doubt he will go on to make incredible contributions to the field! Congratulations Ethan! @MDAndersonNews…
Congratulations to ASTCT New Investigator Award recipient Ye Ethan Li, MD, PhD, of @MDAndersonNews. #Tandem25
Fabulous resource preprint from @yarmo111 @nyulangone A pan-cancer atlas of T cell targets Integrating data from ~7500 RNA seq datasets, >1500 immunopeptidomes & >200 cancer scRNA Seq datasets. Identifying a large series of canonical & non-canonical antigens, novel self…
1/5 Thrilled to share in @NatureComms the clinical outcomes and scRNA-seq correlatives our phase I triplet immunotherapy (IO + IO + TKI) trial in clear cell #kidney cancer: nature.com/articles/s4146…